Clinicaltrials.gov identifier:
NCT02912559 (https://clinicaltrials.gov/show/NCT02912559)
Study Contact Information:
For additional information, please contact: Principal Investigator: Frank A Sinicrope, Alliance for Clinical Trials in Oncology
Immunotherapy may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This phase III trial is for people with stage 3 colon cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment with combination chemotherapy agents alone. This study is focused on patients who have a biomarker known as MSI-High or dMMR, which are commonly seen in people with Lynch syndrome. NOTE: This study is no longer enrolling people.
People will be assigned randomly to one of two groups:
Group 1: Chemotherapy and immunotherapy
Group 2: Chemotherapy only
Both groups of participants will be followed for up to 5 years.
Men or women age 18 years or older can participate if they:
Patients will be excluded if they:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.